Inhibitory innate receptors and their potential role in transplantation.

[1]  P. Lan,et al.  Activation of immune signals during organ transplantation , 2023, Signal Transduction and Targeted Therapy.

[2]  L. Boon,et al.  SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses , 2022, Nature Immunology.

[3]  K. Aoki,et al.  Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer’s disease , 2022, The Journal of biological chemistry.

[4]  N. Luo,et al.  Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types , 2022, Frontiers in Molecular Biosciences.

[5]  M. Tsao,et al.  Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma , 2021, Cancers.

[6]  V. Peperzak,et al.  Inhibitory pattern recognition receptors , 2021, The Journal of experimental medicine.

[7]  L. Giron,et al.  Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity , 2021, Frontiers in Oncology.

[8]  L. Sokol,et al.  Targeting CD22 for the Treatment of B-Cell Malignancies , 2021, ImmunoTargets and therapy.

[9]  Xiao-dong Zhu,et al.  Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma , 2021, Experimental Hematology & Oncology.

[10]  E. Carosella,et al.  HLA-G/LILRBs: A Cancer Immunotherapy Challenge. , 2021, Trends in cancer.

[11]  K. Davis,et al.  CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. , 2020, Blood.

[12]  Y. Hamamoto,et al.  Siglec-7 is a predictive biomarker for the efficacy of cancer vaccination against metastatic colorectal cancer , 2020, Oncology letters.

[13]  J. Murray,et al.  Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. , 2020, The New England journal of medicine.

[14]  C. Redman,et al.  Glycosylated Siglec-6 expression in syncytiotrophoblast-derived extracellular vesicles from preeclampsia placentas. , 2020, Biochemical and biophysical research communications.

[15]  P. M. Nair,et al.  A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation , 2020, Mucosal Immunology.

[16]  J. Borghans,et al.  Functional categories of immune inhibitory receptors , 2020, Nature Reviews Immunology.

[17]  B. Lambrecht,et al.  An anti‐siglec‐8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  Q. Su,et al.  Association of circulating CEACAM1 levels and insulin sensitivity in gestational diabetes mellitus , 2020, BMC Endocrine Disorders.

[19]  P. Crocker,et al.  Siglec-E retards atherosclerosis by inhibiting CD36-mediated foam cell formation , 2020, Journal of Biomedical Science.

[20]  D. Gjertson,et al.  Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. , 2020, The Journal of clinical investigation.

[21]  O. Mandelboim,et al.  Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. , 2020, Pharmacological research.

[22]  G. Remuzzi,et al.  Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c+F4/80+ Macrophages through IL-1R8 Regulation. , 2020, Journal of the American Society of Nephrology : JASN.

[23]  J. Asara,et al.  Targeted deletion of PD-1 in myeloid cells induces antitumor immunity , 2020, Science Immunology.

[24]  G. Gambaro,et al.  Effects of Antirejection Drugs on Innate Immune Cells After Kidney Transplantation , 2019, Front. Immunol..

[25]  Ioannis N. Melas,et al.  Rheumatoid arthritis patients display B-cell dysregulation already in the naïve repertoire consistent with defects in B-cell tolerance , 2019, Scientific Reports.

[26]  Rachel E. Brewer,et al.  CD24 signalling through macrophage Siglec-10 is a new target for cancer immunotherapy , 2019, Nature.

[27]  M. Raftery,et al.  The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance , 2019, Front. Cell. Infect. Microbiol..

[28]  S. Watson,et al.  LAIR-1 Limits Neutrophilic Airway Inflammation , 2019, Front. Immunol..

[29]  K. Maenaka,et al.  HLA‐G dimer targets Granzyme B pathway to prolong human renal allograft survival , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  Yang Liu,et al.  Siglec genes confer resistance to systemic lupus erythematosus in humans and mice , 2018, Cellular & Molecular Immunology.

[31]  Y. Kooyk,et al.  The tumour glyco-code as a novel immune checkpoint for immunotherapy , 2018, Nature Reviews Immunology.

[32]  M. Goumans,et al.  Leukocyte-Associated Immunoglobulin-like Receptor-1 is regulated in human myocardial infarction but its absence does not affect infarct size in mice , 2017, Scientific Reports.

[33]  J. Coligan,et al.  The Role of Leukocyte-Associated Ig-like Receptor-1 in Suppressing Collagen-Induced Arthritis , 2017, The Journal of Immunology.

[34]  Jianping Zhao,et al.  Increased expression of Siglec-9 in chronic obstructive pulmonary disease , 2017, Scientific Reports.

[35]  S. Palmer,et al.  Danger signals in regulating the immune response to solid organ transplantation , 2017, The Journal of clinical investigation.

[36]  Shu-Hsia Chen,et al.  LILRB receptor-mediated regulation of myeloid cell maturation and function , 2017, Cancer Immunology, Immunotherapy.

[37]  X. Wang,et al.  Siglec‐9 is upregulated in rheumatoid arthritis and suppresses collagen‐induced arthritis through reciprocal regulation of Th17‐/Treg‐cell differentiation , 2017, Scandinavian journal of immunology.

[38]  L. Riella,et al.  Treg‐Centric View of Immunosuppressive Drugs in Transplantation: A Balancing Act , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  Jing Wu,et al.  PD-1/PD-L pathway inhibits M.tb-specific CD4+ T-cell functions and phagocytosis of macrophages in active tuberculosis , 2016, Scientific Reports.

[40]  C. Li,et al.  Short‐term MyD88 inhibition ameliorates cardiac graft rejection and promotes donor‐specific hyporesponsiveness of skin grafts in mice , 2016, Transplant international : official journal of the European Society for Organ Transplantation.

[41]  S. Chadban,et al.  Role of TLRs and DAMPs in allograft inflammation and transplant outcomes , 2016, Nature Reviews Nephrology.

[42]  T. Sparwasser,et al.  Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells , 2016, Proceedings of the National Academy of Sciences.

[43]  V. Nizet,et al.  Immunomodulatory activity of extracellular Hsp70 mediated via paired receptors Siglec‐5 and Siglec‐14 , 2015, The EMBO journal.

[44]  S. Calderwood,et al.  Siglecs take a TOLL on inflammation: deciphering the Hsp70 riddle , 2015, The EMBO journal.

[45]  Hao Wang,et al.  Therapeutic lymphangiogenesis ameliorates established acute lung allograft rejection. , 2015, The Journal of clinical investigation.

[46]  J. F. Burrows,et al.  Targeting Siglecs with a sialic acid–decorated nanoparticle abrogates inflammation , 2015, Science Translational Medicine.

[47]  H. Arase,et al.  Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations , 2015, Journal of Human Genetics.

[48]  A. Iwasaki,et al.  Control of adaptive immunity by the innate immune system , 2015, Nature Immunology.

[49]  Zhigang Lu,et al.  The ITIM-containing receptor LAIR1 is essential for acute myeloid leukemia development , 2015, Nature Cell Biology.

[50]  R. Küppers,et al.  CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production , 2015, Nature Communications.

[51]  J. Paulson,et al.  Siglec-mediated regulation of immune cell function in disease , 2014, Nature Reviews Immunology.

[52]  Xi Chen,et al.  Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1 , 2014, eLife.

[53]  H. Haagsman,et al.  Leukocyte‐associated Ig‐like receptor‐1 is a novel inhibitory receptor for surfactant protein D , 2014, Journal of leukocyte biology.

[54]  J. Friedewald,et al.  Molecular Classifiers for Acute Kidney Transplant Rejection in Peripheral Blood by Whole Genome Gene Expression Profiling , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[55]  L. Gesualdo,et al.  Rapamycin induces ILT3(high)ILT4(high) dendritic cells promoting a new immunoregulatory pathway. , 2014, Kidney international.

[56]  J. Connolly,et al.  Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue , 2014, Proceedings of the National Academy of Sciences.

[57]  L. Mishra,et al.  CEACAM1 Long Cytoplasmic Domain Isoform is Associated with Invasion and Recurrence of Hepatocellular Carcinoma , 2014, Annals of Surgical Oncology.

[58]  J. Ochando,et al.  Monocytic Myeloid‐Derived Suppressor Cells Accumulate in Renal Transplant Patients and Mediate CD4+Foxp3+ Treg Expansion , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[59]  P. Romero,et al.  Siglec-7/-9 ligands shield tumor cells from NK cell attack , 2013, Journal of Immunotherapy for Cancer.

[60]  C. Hack,et al.  Inhibition of the Classical and Lectin Pathway of the Complement System by Recombinant LAIR-2 , 2013, Journal of Innate Immunity.

[61]  F. Barré-Sinoussi,et al.  S100A9 protein is a novel ligand for the CD85j receptor and its interaction is implicated in the control of HIV-1 replication by NK cells , 2013, Retrovirology.

[62]  E. Levy,et al.  Ceacam1 deletion causes vascular alterations in large vessels. , 2013, American journal of physiology. Endocrinology and metabolism.

[63]  V. Winn,et al.  Siglec-6 Expression Is Increased in Placentas From Pregnancies Complicated by Preterm Preeclampsia , 2013, Reproductive Sciences.

[64]  D. Merlo,et al.  Serum LAIR-2 Is Increased in Autoimmune Thyroid Diseases , 2013, PloS one.

[65]  A. Prescott,et al.  Siglec-E is a negative regulator of acute pulmonary neutrophil inflammation and suppresses CD11b β2-integrin-dependent signaling. , 2013, Blood.

[66]  N. Beauchemin,et al.  Host-related carcinoembryonic antigen cell adhesion molecule 1 promotes metastasis of colorectal cancer , 2013, Oncogene.

[67]  E. Klechevsky,et al.  Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming , 2012, Proceedings of the National Academy of Sciences.

[68]  B. Diamond,et al.  C1q limits dendritic cell differentiation and activation by engaging LAIR-1 , 2012, Proceedings of the National Academy of Sciences.

[69]  A. Sharpe,et al.  Role of the PD‐1 Pathway in the Immune Response , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[70]  S. Chadban,et al.  Absence of MyD88 signaling induces donor-specific kidney allograft tolerance. , 2012, Journal of the American Society of Nephrology : JASN.

[71]  A. Poggi,et al.  Correction: Defective Expression and Function of the Leukocyte Associated Ig-like Receptor 1 in B Lymphocytes from Systemic Lupus Erythematosus Patients , 2012, PLoS ONE.

[72]  Takashi Saito,et al.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 , 2012, The Journal of experimental medicine.

[73]  E. Ward,et al.  Inhibitory receptors bind Angptls and support blood stem cells and leukemia development , 2012, Nature.

[74]  O. Mandelboim,et al.  CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells , 2011, The Journal of experimental medicine.

[75]  J. V. van Roon,et al.  Enhanced secretion of leukocyte-associated immunoglobulin-like receptor 2 (LAIR-2) and soluble LAIR-1 in rheumatoid arthritis: LAIR-2 is a more efficient antagonist of the LAIR-1-collagen inhibitory interaction than is soluble LAIR-1. , 2011, Arthritis and rheumatism.

[76]  M. Albert,et al.  Visualizing the innate and adaptive immune responses underlying allograft rejection by two-photon microscopy , 2011, Nature Medicine.

[77]  C. Divino,et al.  Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. , 2011, Immunity.

[78]  Des C. Jones,et al.  HLA Class I Allelic Sequence and Conformation Regulate Leukocyte Ig-Like Receptor Binding , 2011, The Journal of Immunology.

[79]  H. Neumann,et al.  Microglial Immunoreceptor Tyrosine-Based Activation and Inhibition Motif Signaling in Neuroinflammation , 2010, International journal of Alzheimer's disease.

[80]  H. Neumann,et al.  Alleviation of Neurotoxicity by Microglial Human Siglec-11 , 2010, The Journal of Neuroscience.

[81]  J. F. Burrows,et al.  Siglec-E Is Up-Regulated and Phosphorylated Following Lipopolysaccharide Stimulation in Order to Limit TLR-Driven Cytokine Production1 , 2009, The Journal of Immunology.

[82]  N. Rouas-Freiss,et al.  Dendritic Cells Secrete the Immunosuppressive HLA-G Molecule upon CTLA4-Ig Treatment: Implication in Human Renal Transplant Acceptance1 , 2009, The Journal of Immunology.

[83]  V. Rao,et al.  Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[84]  V. Nizet,et al.  Group B Streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5 , 2009, The Journal of experimental medicine.

[85]  D. von Bubnoff,et al.  Tryptophan Deprivation Induces Inhibitory Receptors ILT3 and ILT4 on Dendritic Cells Favoring the Induction of Human CD4+CD25+ Foxp3+ T Regulatory Cells1 , 2009, The Journal of Immunology.

[86]  M. Mihatsch,et al.  Expression of carcinoembryonic antigen-related cell adhesion molecule 1 in acute rejection of human renal allografts. , 2009, Transplantation proceedings.

[87]  T. V. van Gulik,et al.  Complement-Mediated Ischemia-Reperfusion Injury: Lessons Learned From Animal and Clinical Studies , 2009, Annals of surgery.

[88]  James C Paulson,et al.  Siglecs as targets for therapy in immune-cell-mediated disease. , 2009, Trends in pharmacological sciences.

[89]  C. Chung,et al.  PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis , 2009, Proceedings of the National Academy of Sciences.

[90]  J. Bluestone,et al.  Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes , 2008, Diabetes.

[91]  Wei Zhang,et al.  Human Inhibitory Receptor Immunoglobulin-Like Transcript 2 Amplifies CD11b+Gr1+ Myeloid-Derived Suppressor Cells That Promote Long-Term Survival of Allografts , 2008, Transplantation.

[92]  M. Gobbi,et al.  Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division , 2008, Leukemia.

[93]  L. Meyaard.  The inhibitory collagen receptor LAIR‐1 (CD305) , 2008, Journal of leukocyte biology.

[94]  J. Trowsdale,et al.  The inhibitory receptor LILRB1 modulates the differentiation and regulatory potential of human dendritic cells. , 2008, Blood.

[95]  P. Lenting,et al.  The Soluble Leukocyte-Associated Ig-Like Receptor (LAIR)-2 Antagonizes the Collagen/LAIR-1 Inhibitory Immune Interaction1 , 2008, The Journal of Immunology.

[96]  Y. Takasaki,et al.  Expression of CD22 on peripheral B cells in patients with rheumatoid arthritis: relation to CD5-positive B cells , 2007, Clinical Rheumatology.

[97]  C. Jansen,et al.  Regulated expression of the inhibitory receptor LAIR‐1 on human peripheral T cells during T cell activation and differentiation , 2007, European journal of immunology.

[98]  S. Akira,et al.  TLR Engagement Prevents Transplantation Tolerance , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[99]  M. Czerny,et al.  Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies , 2006, Allergy.

[100]  C. Johnsson,et al.  Serum hyaluronan--a potential marker of cardiac allograft rejection? , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[101]  C. Geest,et al.  Differential expression of leukocyte‐associated Ig‐like receptor‐1 during neutrophil differentiation and activation , 2006, Journal of leukocyte biology.

[102]  D. Greiner,et al.  TLR Agonists Abrogate Costimulation Blockade-Induced Prolongation of Skin Allografts1 , 2006, The Journal of Immunology.

[103]  P. Bousso,et al.  CD4 T cells integrate signals delivered during successive DC encounters in vivo , 2005, The Journal of experimental medicine.

[104]  J. Coligan,et al.  The inhibitory leukocyte-associated Ig-like receptor-1 (LAIR-1) is expressed at high levels by human naive T cells and inhibits TCR mediated activation. , 2005, Molecular immunology.

[105]  M. Neumaier,et al.  The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis , 2004, Oncogene.

[106]  W. Ouyang,et al.  Establishment of an ELISA system for determining soluble LAIR-1 levels in sera of patients with HFRS and kidney transplant. , 2004, Journal of immunological methods.

[107]  R. Lebbink,et al.  The Mouse Homologue of the Leukocyte-Associated Ig-Like Receptor-1 Is an Inhibitory Receptor That Recruits Src Homology Region 2-Containing Protein Tyrosine Phosphatase (SHP)-2, but Not SHP-11 , 2004, The Journal of Immunology.

[108]  W. Ouyang,et al.  9.1C3 is identical to LAIR-1, which is expressed on hematopoietic progenitors. , 2003, Biochemical and biophysical research communications.

[109]  S. Akira,et al.  Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. , 2003, The Journal of clinical investigation.

[110]  R. Tan,et al.  Chronic Active Epstein–Barr Virus Infection Associated with Low Expression of Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) on Natural Killer Cells , 2003, Journal of Clinical Immunology.

[111]  U. Schumacher,et al.  Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  S. Najjar.  Regulation of insulin action by CEACAM1 , 2002, Trends in Endocrinology & Metabolism.

[113]  A. Nakamura,et al.  Impaired dendritic cell maturation and increased TH2 responses in PIR-B−/− mice , 2002, Nature Immunology.

[114]  U. Schumacher,et al.  CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  M. Colonna,et al.  Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4 , 2002, Nature Immunology.

[116]  M. Gobbi,et al.  Leukocyte‐associated Ig‐like receptor‐1 prevents granulocyte‐monocyte colony stimulating factor‐dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells , 2001, European journal of immunology.

[117]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  I. Bernstein,et al.  Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. , 2001, Blood.

[119]  N. Beauchemin,et al.  The CEACAM1-L Ser503 residue is crucial for inhibition of colon cancer cell tumorigenicity , 2001, Oncogene.

[120]  S. Ergün,et al.  Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1. , 2000, Experimental cell research.

[121]  M. Vawter,et al.  Dysregulation of the neural cell adhesion molecule and neuropsychiatric disorders. , 2000, European journal of pharmacology.

[122]  Isabelle Durand,et al.  FDF03, a Novel Inhibitory Receptor of the Immunoglobulin Superfamily, Is Expressed by Human Dendritic and Myeloid Cells1 , 2000, The Journal of Immunology.

[123]  N. Beauchemin,et al.  cis-Determinants in the cytoplasmic domain of CEACAM1 responsible for its tumor inhibitory function , 1999, Oncogene.

[124]  I. Bernstein,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate , 2017 .

[125]  H Clevers,et al.  Leukocyte-associated Ig-like receptor-1 functions as an inhibitory receptor on cytotoxic T cells. , 1999, Journal of immunology.

[126]  M. Colonna,et al.  Cutting Edge: Human Myeloid Cells Express an Activating ILT Receptor (ILT1) That Associates with Fc Receptor γ-Chain , 1999, The Journal of Immunology.

[127]  S. von Kleist,et al.  Biliary glycoprotein (CD66a), a cell adhesion molecule of the immunoglobulin superfamily, on human lymphocytes: structure, expression and involvement in T cell activation , 1998, European journal of immunology.

[128]  L. Moretta,et al.  p40/LAIR‐1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte‐monocyte colony‐stimulating factor , 1998, European journal of immunology.

[129]  V. Cerundolo,et al.  Cutting Edge: Human Myelomonocytic Cells Express an Inhibitory Receptor for Classical and Nonclassical MHC Class I Molecules , 1998, The Journal of Immunology.

[130]  M. Colonna,et al.  A Common Inhibitory Receptor for Major Histocompatibility Complex Class I Molecules on Human Lymphoid and Myelomonocytic Cells , 1997, The Journal of experimental medicine.

[131]  L. Moretta,et al.  p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes. , 1997, International immunology.

[132]  L Meyaard,et al.  LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. , 1997, Immunity.

[133]  N. Beauchemin,et al.  Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells , 1997, Oncogene.

[134]  M. Neumaier,et al.  CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[135]  S. Pham,et al.  Monitoring of acute lung rejection and infection by bronchoalveolar lavage and plasma levels of hyaluronic acid in clinical lung transplantation. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[136]  H. Katz.  Inhibition of inflammatory responses by leukocyte Ig-like receptors. , 2006, Advances in immunology.

[137]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.